With ever-increasing drug resistant clinical isolates, novel antibiotics with new targets are
urgently needed. Tuberculosis, caused by Mycobacterium tuberculosis, showed formidable antibiotics
resistance. InhA, the enoyl-acyl carrier protein (ACP) reductase involved in the type II fatty acid synthesis
pathway (FASII) in Mycobacterium tuberculosis, represents an appealing target for the development
of new anti-tuberculosis (TB) agents. Inhibitors against InhA might be ideal lead or antibiotics.
The latest development of InhA inhibitors is summarized in this paper.
Keywords: Drug discovery, drug resistance, enoyl-ACP reductase, InhA, isoniazid, tuberculosis.
Rights & PermissionsPrintExport